Incyte (INCY) Interest & Investment Income (2010 - 2026)
Incyte's (INCY) quarterly Interest & Investment Income came in at $38.1 million in Q2 2026, up 51.65% YoY from $25.1 million in Q2 2025, and up 13.15% on a QoQ basis from $33.7 million in Q1 2026.
Analysis
Incyte (INCY) Interest & Investment Income (2010 - 2026) Analysis & Trends
Incyte (INCY) has 11 years of Interest & Investment Income data on file, last reported at $38.1 million in Q2 2026.
- Quarterly Interest & Investment Income rose 51.65% year-over-year to $38.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $129.3 million (up 46.1% YoY) and the FY2025 annual result came in at $105.6 million, down 17.96% from the prior year.
- Interest & Investment Income rose to $38.1 million in Q2 2026, from $33.7 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $46.8 million in Q1 2024 to a low of $19.3 million in Q3 2024.
- A 3-year average of $30.6 million and a median of $28.8 million in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2025 — Interest & Investment Income slumped 50.97% — and 2026, when it soared 51.65%.
- Tracing INCY's Interest & Investment Income over 3 years: stood at $21.2 million in 2024, then surged by 45.08% to $30.8 million in 2025, then increased by 23.94% to $38.1 million in 2026.
- The last three Interest & Investment Income figures came in at $38.1 million (Q2 2026), $33.7 million (Q1 2026), and $30.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.80 Bn | 130.95 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.54 Bn | 77.55 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.40 Bn | 32.09 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.57 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Incyte | 25.62 Bn | 21.08 Bn | 1.57 Bn | 38.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 38.12 Mn |
| Mar 31, 2026 | 33.69 Mn |
| Dec 31, 2025 | 30.75 Mn |
| Sep 30, 2025 | 26.78 Mn |
| Jun 30, 2025 | 25.14 Mn |
| Mar 31, 2025 | 22.93 Mn |
| Dec 31, 2024 | 21.20 Mn |
| Sep 30, 2024 | 19.27 Mn |
| Jun 30, 2024 | 41.48 Mn |
| Mar 31, 2024 | 46.77 Mn |
| Dec 31, 2017 | 6.27 Mn |
| Sep 30, 2017 | 5.56 Mn |
| Jun 30, 2017 | 4.13 Mn |
| Mar 31, 2017 | 1.20 Mn |
| Dec 31, 2016 | 594,000.00 |
| Sep 30, 2016 | 1.19 Mn |
| Jun 30, 2016 | 1.14 Mn |
| Mar 31, 2016 | 1.49 Mn |
| Dec 31, 2015 | 1.29 Mn |
| Sep 30, 2015 | 3.03 Mn |